{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumor+of+the+Lung",
    "query": {
      "condition": "Neuroendocrine Tumor of the Lung"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 533,
    "total_pages": 54,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumor+of+the+Lung&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T04:03:13.868Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06131398",
      "title": "A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "AMG 355",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 77,
      "start_date": "2024-03-07",
      "completion_date": "2026-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Merriam",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06131398"
    },
    {
      "nct_id": "NCT03361228",
      "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "INCB001158",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-03-01",
      "completion_date": "2019-03-30",
      "has_results": true,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03361228"
    },
    {
      "nct_id": "NCT06894771",
      "title": "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "MK-4700",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2025-04-23",
      "completion_date": "2025-12-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 2,
      "location_summary": "Hackensack, New Jersey • San Antonio, Texas",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06894771"
    },
    {
      "nct_id": "NCT00346385",
      "title": "BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Merkel Cell Carcinoma",
        "SCLC"
      ],
      "interventions": [
        {
          "name": "BB-10901",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunoGen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2002-03",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2015-03-26",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Las Vegas, Nevada • Columbus, Ohio + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00346385"
    },
    {
      "nct_id": "NCT04837677",
      "title": "A Study of PRT1419 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma",
        "Melanoma",
        "Lung Cancer",
        "Breast Cancer",
        "Esophageal Cancer",
        "Cervical Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "PRT1419",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prelude Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-08-11",
      "completion_date": "2023-02-06",
      "has_results": false,
      "last_update_posted_date": "2023-03-15",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 7,
      "location_summary": "Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04837677"
    },
    {
      "nct_id": "NCT02576431",
      "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors Harboring NTRK Fusion"
      ],
      "interventions": [
        {
          "name": "BAY2757556 (Larotrectinib, Vitrakvi)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2015-09-30",
      "completion_date": "2025-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 18,
      "location_summary": "Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02576431"
    },
    {
      "nct_id": "NCT03412877",
      "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endocrine Tumors",
        "Non-Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Gastrointestinal/Genitourinary Cancers",
        "Neuroendocrine Tumors",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Individual Patient TCR-Transduced PBL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA(R))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 285,
      "start_date": "2018-09-06",
      "completion_date": "2028-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03412877"
    },
    {
      "nct_id": "NCT06546553",
      "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Non-small-cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-07826390",
          "type": "DRUG"
        },
        {
          "name": "sasanlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SOC (anti-PD-1 + platinum -based chemo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-09-06",
      "completion_date": "2025-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06546553"
    },
    {
      "nct_id": "NCT03957096",
      "title": "A Safety Study of SGN-CD47M in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Soft Tissue Sarcoma",
        "Colorectal Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Breast Carcinoma",
        "Ovarian Carcinoma",
        "Exocrine Pancreatic Carcinoma",
        "Gastric Carcinoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "SGN-CD47M",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2019-07-17",
      "completion_date": "2020-09-14",
      "has_results": false,
      "last_update_posted_date": "2020-09-17",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 5,
      "location_summary": "Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03957096"
    },
    {
      "nct_id": "NCT00986661",
      "title": "A Study to Assess PV-10 Chemoablation of Cancer of the Liver",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer Metastatic to the Liver",
        "Hepatocellular Carcinoma",
        "Metastatic Melanoma",
        "Metastatic Ocular Melanoma",
        "Metastatic Uveal Melanoma",
        "Metastatic Lung Cancer",
        "Metastatic Colon Cancer",
        "Metastatic Colorectal Cancer",
        "Metastatic Breast Cancer",
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "PV-10 (10% rose bengal disodium)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Provectus Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2009-10",
      "completion_date": "2023-02",
      "has_results": false,
      "last_update_posted_date": "2022-11-02",
      "last_synced_at": "2026-06-10T04:03:13.868Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Tampa, Florida • Bethlehem, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Bethlehem",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00986661"
    }
  ]
}